Use of chloramphenicol as topical eye medication: time to cry halt?BMJ 1995; 310 doi: http://dx.doi.org/10.1136/bmj.310.6989.1217 (Published 13 May 1995) Cite this as: BMJ 1995;310:1217
- Marie Doona,
- J Bernard Walsh
- Registrar Consultant physician Department of Medicine for the Elderly, St James's Hospital, Dublin 8, Republic of Ireland
Bone marrow aplasia also occurs with ocular use
Chloramphenicol accounts for over half the general medical services prescriptions for ocular antibiotics in the Republic of Ireland, while in the United Kingdom 55% of patients presenting to general practitioners with “red eyes” are treated with chloramphenicol eye ointment.1 The British National Formulary currently recommends chloramphenicol as the drug of choice for superficial eye infections. It has the advantage that it has a broad spectrum of activity and rarely causes local irritation or hypersensitivity, which may be a problem with other antibiotics. Yet on our wards we no longer prescribe topical ocular chloramphenicol. Why?
Since 1950, when Rich et al highlighted the relation between oral chloramphenicol and bone marrow aplasia,2 doctors have been well aware of this side effect. The first death resulting from bone marrow aplasia induced by chloramphenicol eye drops was described by Rosenthal and Blackman in 1955.3 Numerous subsequent …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial